Compare MGM Resorts International (MGM) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? MGM Resorts International trades at $29.12 (market cap $7.29B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is the larger of the two by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 92 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| MGM | RDY | |
|---|---|---|
Market Cap | $7.29B | $10.61B |
Volume | 4,222,588 | 3,738,869 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $15.38 |
52-Week Low | $28.96 | $11.38 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $34.59B | $10.51B |
Dividend Yield | 0.03% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $29.40, down 17% year-to-date amid failed acquisition talks with Barry Diller's People Inc. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining profit margins despite steady revenue growth. Recent news highlights volatile deal-making activity, with MGM now considering a reverse bid for People Inc. after Diller withdrew his $48.30 per share offer in September 2026.
Analysts maintain a bullish consensus with a $47.57 price target, representing 62% upside potential. Key risks include execution challenges in potential acquisitions, declining profitability margins, and high debt levels. The upcoming Q3 2026 earnings report on October 28 will be critical for validating the company's turnaround prospects amid ongoing strategic uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Dr. Reddy's Laboratories Ltd Common Stock
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →
